Qiyu Li
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2023
10.08.2023Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
10.08.2023JAMA Oncol 2023
Huober Jens, Weder Patrik, Ribi Karin, Thürlimann Beat, Thery Jean-Christophe, Li Qiyu, Vanlemmens Laurence, Guiu Séverine, Brain Etienne, Grenier Julien, Dalenc Florence, Levy Christelle, Savoye Aude-Marie, Müller Andreas S, Membrez-Antonioli Véronique, Gerard Marie-Aline, Lemonnier Jérôme, Hawle Hanne, Dietrich Daniel, Boven Epie, Bonnefoi Hervé R, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group
Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. Int J Radiat Oncol Biol Phys 2022; 113:80-91.
03.01.2022Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
03.01.2022Int J Radiat Oncol Biol Phys 2022; 113:80-91
Beck Marcus, Li Qiyu, Sumila Marcin, Zaugg Kathrin, Guckenberger Matthias, Ost Piet, Bosetti Davide G, Reuter Christiane, Gomez Silvia, Khanfir Kaouthar, Aebersold Daniel M, Ghadjar Pirus, Schär Corinne, Hayoz Stefanie, Papachristofilou Alexandros, Sassowsky Manfred, Schär Sämi, Mathier Etienne, Halter Matthias, Zwahlen Daniel R, Hölscher Tobias, Arnold Winfried, Polat Bülent, Hildebrandt Guido, Müller Arndt-Christian, Putora Paul Martin, Pra Alan Dal
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
25.04.2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
25.04.2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Brune M, Cogliatti S, Ossenkoppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol 2021; 100:1169-1179.
02.03.2021Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
02.03.2021Ann Hematol 2021; 100:1169-1179
Brune Magdalena M, Cogliatti Sergio B., Ossenkoppele Gert J, Löwenberg Bob, Rudolf Christina Biaggi, Li Qiyu, Passweg Jakob, Mazzuchelli Luca, Medinger Michael, Tzankov Alexandar, Fehr Martin, Grobholz Rainer, Stussi Georg, Lundberg Pontus, Vela Visar, Heim Dominik, Manz Markus G, Haralambieva Eugenia, Pabst Thomas, Banz Yara, Bargetzi Mario, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
19.09.2019Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
19.09.2019Sci Rep 2019; 9:13534
Varga Zsuzsanna, Thürlimann Beat, Klingbiel Dirk, Hawle Hanne, Tille Jean-Christoph, Rau Tilman, Perriard Ulrike, Jochum Wolfram, Li Qiyu, Ruhstaller Thomas
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018
31.08.2018Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
31.08.2018Cancer Immunol Immunother 2018
Schmid Sabine, Jochum Wolfram, Klingbiel Dirk, Desbiolles Lotus, Leschka Sebastian, Flatz Lukas, Krapf Mirjam, Li Qiyu, Diem Stefan, Früh Martin
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
23.11.2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
23.11.2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PloS one 2015; 10:e0123435.
17.04.2015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
17.04.2015PloS one 2015; 10:e0123435
Varga Zsuzsanna, Cassoly Estelle, Li Qiyu, Öhlschlegel Christian, Tapia Coya, Lehr Hans Anton, Klingbiel Dirk, Thürlimann Beat, Ruhstaller Thomas
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
05.03.2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
05.03.2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer 2013; 21:3085-93.
05.07.2013Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
05.07.2013Support Care Cancer 2013; 21:3085-93
Hitz Felicitas, Ribi Karin, Li Qiyu, Klingbiel Dirk, Cerny Thomas, Koeberle Dieter